BioStock: Saniona's CEO on the plans for 2021
Saniona has an ambitious plan for 2021, including advancement of its primary drug candidate Tesomet, which targets the rare diseases hypothalamic obesity (HO) and Prader-Willi syndrome (PWS). Saniona’s US-based CEO Rami Levin talked to BioStock about the plans for the year, including the intention to start Phase IIb studies in both HO and PWS during the first half of the year.
Read the full interview with Rami Levin at biostock.se:
https://www.biostock.se/en/sanionas-ceo-on-the-plans-for-2021/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se